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Information on the stage of liver fibrosis is essential in managing chronic hepatitis C (CHC)
patients. However, most models for predicting liver fibrosis are complicated and separate
formulas are needed to predict significant fibrosis and cirrhosis. The aim of our study was to
construct one simple model consisting of routine laboratory data to predict both significant
fibrosis and cirrhosis among patients with CHC. Consecutive treatment-naive CHC patients
who underwent liver biopsy over a 25-month period were divided into 2 sequential cohorts:
training set (n  192) and validation set (n  78). The best model for predicting both
significant fibrosis (Ishak score > 3) and cirrhosis in the training set included platelets,
aspartate aminotransferase (AST), and alkaline phosphatase with an area under ROC curves
(AUC) of 0.82 and 0.92, respectively. A novel index, AST to platelet ratio index (APRI), was
developed to amplify the opposing effects of liver fibrosis on AST and platelet count. The
AUC of APRI for predicting significant fibrosis and cirrhosis were 0.80 and 0.89, respec-
tively, in the training set. Using optimized cut-off values, significant fibrosis could be
predicted accurately in 51% and cirrhosis in 81% of patients. The AUC of APRI for pre-
dicting significant fibrosis and cirrhosis in the validation set were 0.88 and 0.94, respectively.
In conclusion, our study showed that a simple index using readily available laboratory results
can identify CHC patients with significant fibrosis and cirrhosis with a high degree of
accuracy. Application of this index may decrease the need for staging liver biopsy specimens
among CHC patients. (HEPATOLOGY 2003;38:518-526.)
Histologic examination of the liver is an integralpart of the evaluation of patients with chronichepatitis C (CHC).1,2 Knowledge of the stage of
liver fibrosis is essential for prognostication and decisions
on antiviral treatment.3,4 CHC patients with no or min-
imal fibrosis at presentation appear to progress slowly and
treatment possibly could be delayed or withheld. On the
other hand, patients with significant fibrosis (i.e., septal or
bridging fibrosis) progress almost invariably to cirrhosis
over a 10- to 20- year period so antiviral treatment should
be strongly considered.5 For patients with cirrhosis, sur-
veillance for hepatocellular carcinoma and gastroesopha-
geal varices should be considered also.6,7
Liver biopsy is currently the gold standard in assessing
liver histology. Although percutaneous liver biopsy is in gen-
eral a safe procedure, it is costly and does carry a small risk for
complication.8 In addition, there could be sampling error
because only 1/50,000 of the organ is sampled. Furthermore,
inter- and intraobserver discrepancies of 10% to 20% in
assessing hepatic fibrosis have been reported, which may lead
to understaging of cirrhosis.9-11 Hence, there is a need to
develop accurate and reliable noninvasive means to assess the
severity of hepatic fibrosis.
Noninvasive approaches to assess histology in CHC
patients include clinical symptoms and signs, routine lab-
oratory tests, serum markers of fibrosis and inflammation,
quantitative assays of liver function, and radiologic imag-
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ing studies.12-15 However, at present, none of these tests or
markers alone is accurate or reliable in predicting histol-
ogy, in particular, liver fibrosis. An ideal noninvasive di-
agnostic test for hepatic fibrosis should be simple, readily
available, inexpensive, and accurate.16 An index compris-
ing routinely available laboratory tests would meet these
criteria.
Many studies have been performed to evaluate the use
of readily available laboratory test results to predict signif-
icant fibrosis or cirrhosis in patients with CHC.17-21
However, sensitivity was generally poor, and most studies
did not validate their results in a separate group of pa-
tients. A recent study by Forns et al.21 performed internal
validation using a randomly chosen cohort from the study
patients and found that absence of significant fibrosis
could be predicted in 39% of patients. However, only
24% of their patients had significant fibrosis so it is un-
certain if the results could be extrapolated to patients with
more advanced disease.
For the prediction of cirrhosis, most studies examined
the usefulness of predetermined formulas such as aspar-
tate aminotransferase (AST)/alanine aminotransferase
(ALT) ratio or the cirrhosis discriminant score, without
analyzing other confounding factors or validating their
results.22-26 Kaul et al.27 performed univariate and multi-
variate analysis on 351 patients and derived a model con-
sisting of gender, AST, platelet count, and spider nevi.
This model was validated internally and externally with
good accuracy but it included one subjective variable.
We aimed to develop one single model consisting of
readily available, objective laboratory data to predict both
significant fibrosis and cirrhosis in treatment-naive CHC
patients. To accomplish this, a training set of clinical and
laboratory data from 192 consecutive CHC patients were
used to formulate predictive models, which were vali-
dated in 78 subsequent patients.
Patients and Methods
Patients. This retrospective cohort study included
579 consecutive adult patients with CHC who had un-
dergone percutaneous liver biopsy at the University of
Michigan Medical Center from January 2001 to January
2003. The diagnosis of CHC was established by the pres-
ence of hepatitis C virus (HCV) RNA using polymerase
chain reaction assays. Patients with the following condi-
tions were excluded from the study: presence of other
causes of liver disease, hepatocellular carcinoma, prior
liver transplantation, prior interferon therapy, immuno-
suppressive therapy, insufficient liver tissue for staging of
fibrosis, and incomplete data on complete blood counts
and/or liver panel.
Patients were divided into 2 sets: consecutive patients
who were biopsied between January 2001 and July 2002
constituted the training set, whereas those patients who
were biopsied between August 2002 and January 2003
constituted the validation set. All study subjects gave in-
formed consent for the liver biopsy. This study was ap-
proved by the Institutional Review Board.
Methods. A list of consecutive CHC patients who un-
derwent percutaneous liver biopsy at the University of
Michigan Medical Center was generated from the De-
partment of Pathology. Clinical information about these
patients obtained from electronic medical record and
hard-copy clinical charts were reviewed by one investiga-
tor (C.T.W.) to assess eligibility for the study. Demo-
graphics and laboratory variables were recorded. Other
clinical variables were extracted from the medical records
according to a set of predetermined criteria.
Patients on diabetic medications or patients who had a
past history of diabetes mellitus were considered to have
diabetes mellitus. Patients who had been drinking more
than an average of 7 drinks per week, for more than 4
weeks in a row before the liver biopsy, were considered
current drinkers. Patients who drank less than 7 drinks
per week for the past 4 weeks in a row were considered
nondrinkers. Patients who had stopped drinking com-
pletely for more than 1 year before the biopsy were con-
sidered ex-drinkers. Patients with no explicitly mentioned
amount or duration of drinking were considered to have
an unknown drinking history.
Patients with a history of blood transfusion before
1992 were considered to have acquired CHC through
transfusion.28,29 For those with multiple transfusions,
the date of the first transfusion was considered to be the
time of infection. Patients with a history of injection
drug use (IDU) were considered to have acquired CHC
through IDU and the year in which IDU began was
considered to be the time of infection. Patients with no
history of transfusion or IDU, but who had other
modes of percutaneous exposure such as a tattoo, oc-
cupational exposure, and so forth, were considered to
have acquired CHC through others means and the year
of first percutaneous exposure was considered as the
time of infection. Patients without parenteral risk fac-
tors were considered to be unknown regarding both the
mode and duration of infection.
Except for HCV genotype, only laboratory results per-
formed within 4 months from the date of the liver biopsy
were used for this study. If more than one set of laboratory
test results were available, the results closest to the time of
biopsy were used. Results of serum aminotransferase and
alkaline phosphatase (ALP) levels were expressed as ratios
of the upper limit of normal (ULN). HCV-RNA level was
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expressed as log10 IU/mL. Abdominal ultrasound reports
within 6 months from the time of biopsy were reviewed.
Patients with splenomegaly, enlarged spleen, or spleen
size of more than 14 cm were considered to have spleno-
megaly.30
Histologic slides of all eligible patients were retrieved.
All liver biopsies were reviewed by one pathologist
(J.K.G.), who had no knowledge of the clinical character-
istics of the study subjects. Hepatic fibrosis was assessed
using the Ishak fibrosis score.31 Significant fibrosis was
defined as Ishak score of 3 or more (presence of bridging
fibrosis) and cirrhosis as Ishak score of 5 or 6.
Statistical Analysis. Data were expressed as mean 
SEM unless otherwise stated. Statistical analysis was
performed by SPSS software version 9.0 (SPSS Inc.,
Chicago, IL). There were 2 endpoints in this study:
presence of significant fibrosis and cirrhosis. The fol-
lowing variables were included in the univariate analy-
sis: demographics (age, sex, ethnicity), alcohol intake,
viral factors (mode of HCV infection, age at infection,
duration of infection, HCV-RNA level, genotype), and
other test results (white cell count, platelet count, in-
ternational normalized ratio, bilirubin, albumin, ALT,
AST, and ALP). All continuous variables were analyzed
after logarithmic transformation for normality of dis-
tribution. Categoric variables were compared by 2 or
Fisher exact tests, whereas continuous variables were
compared with the Student’s t test. Correlation was
evaluated by the Spearman correlation coefficient. A
2-sided P value of less than .05 was considered statisti-
cally significant.
For the formulation of predictive models, univariate
analysis was performed on variables between patients with
and without the study endpoints in the training set. Sig-
nificant variables from the univariate analysis (P  .05),
together with age at biopsy, were then subjected to mul-
tivariate analysis by forward logistic regression to identify
independent factors associated with either endpoint.
Variables with missing values in more than 20% of the
patients (i.e., splenomegaly on ultrasonography, body
mass index, age at infection, and duration of infection)
were not included in the regression analysis.
Formulas with risk scores that could best predict the
study endpoints (significant fibrosis and cirrhosis) were
constructed by entering different sets of independent vari-
ables into the regression model. The diagnostic value of
each formula was assessed by the area under the receiver
operating characteristic (ROC) curves.
The best model derived from the training set then was
applied to the validation set to test for accuracy by mea-
suring the areas under the ROC curves.
Results
Characteristics of the Patients in the Training Set.
From January 2001 to July 2002, 428 percutaneous liver
biopsies were performed on patients with CHC at our
institution. A total of 236 patients were excluded from the
study: 102 had prior interferon therapy, 82 had prior liver
transplants, 23 had concomitant liver diseases, 9 were on
immunosuppressive therapy, 4 had insufficient liver tis-
sues for staging of fibrosis, and 16 had incomplete data on
complete blood count and/or liver panel.
The mean age of the 192 patients included in the train-
ing set was 46.8  0.6 years, 123 (64%) were men, 151
(79%) were Caucasians, and 16 (8%) were African Amer-
icans. Thirteen (7%) patients had diabetes mellitus (Ta-
ble 1). The age at infection and duration of infection,
available in 65% of the patients, were 21.1  0.7 years
and 26.7  0.7 years, respectively. Of the 98 patients who
had ultrasound results, 18 (18%) had splenomegaly. The
mean Ishak fibrosis score was 2.83  0.10. Ninety-one






n  78 P Value
Age, y 46.8  0.6 47.7  0.9 .45
Male gender, n (%) 123 (64) 51 (66) .89
Ethnicity, n (%)
Caucasians 151 (77) 48 (62) .014
African Americans 16 (8) 17 (22)
Others 7 (4) 5 (6)
Unknown 18 (9) 8 (10)
Drinking history, n (%)
Current drinker 26 (14) 8 (10) .50
Ex-drinker 54 (28) 18 (23)
Nondrinker 90 (47) 40 (51)
Unknown 20 (11) 12 (15)
Mode of transmission, n (%)
IDU 79 (41) 24 (30) .025
Transfusion 45 (23) 10 (13)
IDU and transfusion 9 (5) 4 (5)
Others 31 (16) 20 (26)
Unknown 28 (15) 20 (26)
Age at infection, y 21.1  0.7 22.5  1.5 .29
Duration of infection, y 26.6  0.7 26.3  1.1 .97
Genotype 1, n (%) 130/173 (75) 52/74 (70) .43
Viral load, log10 (IU/mL) 5.81  0.05 6.11  0.09 .006
White cell count (109/L) 6.6  0.1 6.7  0.2 .65
Platelet count (109/L) 219  5 205  9 .16
International normalized ratio 1.01  0.01 1.01  0.02 .22
Bilirubin (mg/dL) 0.58  0.02 0.61  0.04 .48
Albumin (g/dL) 4.00  0.04 4.09  0.05 .23
ALT (/ULN) 2.63  0.17 2.55  0.27 .51
AST (/ULN) 2.20  0.14 2.35  0.23 .34
ALP (/ULN) 0.64  0.02 0.71  0.03 .016
Ishak fibrosis score 2.83  0.10 2.88  0.17 .77
Significant fibrosis, n (%) 91 (47) 39 (50) .79
Cirrhosis, n (%) 28 (15) 13 (17) .71
NOTE. Values are expressed as mean  SEM.
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(47%) patients had significant fibrosis and 28 (15%) had
cirrhosis.
Predictors of Significant Fibrosis and Cirrhosis
From the Training Set. Variables associated with the
presence of significant fibrosis and cirrhosis were first as-
sessed by univariate analysis (Table 2). Subsequent mul-
tivariate analysis showed that platelet count (P  .001),
AST level (P  .001), and ALP level (P  .029) were the
independent predictors of significant fibrosis whereas
platelet count (P  .001), AST level (P  .017), white cell
count (P  .01), ALP level (P  .019), and AST/ALT
ratio (P  .001) were the independent predictors of cir-
rhosis.
Variables in the best models for prediction of signifi-
cant fibrosis included platelet count, AST levels, and ALP
levels, and for prediction of cirrhosis platelet count, white
cell count, AST level, ALP level, and AST/ALT ratio (Ta-
ble 3). Models with only platelet count and AST level
were more simple and had accuracies comparable with
those with 3 or more variables in prediction of both end-
points.
Regression formula for prediction of significant fibrosis:
Risk score  2.318
 0.274ln (AST level [/ULN])
 0.375ln (platelet count [109/L]).
Regression formula for prediction of cirrhosis:
Risk score  2.411
 0.100ln (AST level [/ULN])
 0.436ln (platelet count [109/L]).
Although both histologic endpoints could be predicted by
the same variables, 2 separate formulas were required and
cumbersome calculation was needed.
Validation Set. From August 2002 to January 2003,
151 liver biopsies were performed on adult patients with
CHC. Seventy-three patients were excluded from the
study: 39 had prior interferon therapy, 23 had prior liver
transplant, 5 had concomitant liver diseases, 2 were on
immunosuppressive therapy, and 4 had incomplete re-
Table 2. Univariate Analysis of Variables Associated With the Presence of Significant Fibrosis













(n  28) P Value
Age, y 45.5  0.8 47.9  0.9 .069 46.5  0.6 47.7  1.7 .54
Male gender, n (%) 60 (59) 60 (69) .18 101 (62) 22 (79) .092
Ethnicity, n (%)
Caucasians 77 (76) 74 (81) .13 128 (78) 23 (83) .40
African Americans 12 (12) 4 (4) 15 (9) 1 (4)
Others 5 (5) 2 (2) 7 (4) 0
Unknown 7 (7) 11 (12) 14 (9) 4 (13)
Drinking history, n (%)
Current drinker 2 (12) 14 (15) .106 23 (14) 3 (11) .20
Ex-drinker 22 (22) 32 (35) 42 (26) 12 (43)
Nondrinker 55 (56) 35 (39) 81 (50) 9 (32)
Unknown 10 (10) 10 (11) 16 (10) 4 (14)
Mode of transmission, n (%)
IDU 45 (44) 34 (37) .009 68 (42) 11 (39) .004
Transfusion 20 (20) 25 (28) 39 (24) 6 (18)
IDU and transfusion 0 9 (10) 4 (2) 5 (21)
Others 19 (19) 12 (13) 30 (18) 1 (4)
Unknown 17 (17) 11 (12) 23 (14) 5 (18)
Age at infection, y 20.4  0.8 21.9  1.2 .29 21.1  0.8 21.1  1.8 .61
Duration of infection, y 25.9  0.9 27.7  1.1 .32 26.5  0.8 27.7  2.0 .47
Genotype 1, n (%) 67/90 (75) 63/83 (76) .86 112/149 (75) 18/24 (76) 1.00
HCV-RNA titer, log10 (IU/mL) 5.73  0.07 5.91  0.08 .091 5.82  0.05 5.76  0.16 .73
White cell count (109/L) 6.8  0.2 6.3  0.2 .033 6.7  0.2 5.7  0.4 .015
Platelet count (109/L) 246  6 140  8 .001 234  5 136  11 .001
INR 0.99  0.01 1.04  0.01 .001 1.00  0.01 1.09  0.02 .001
Bilirubin (mg/dL) 0.52  0.03 0.64  0.04 .009 0.55  0.02 0.75  0.09 .008
Albumin (g/dL) 4.8  0.5 4.3  0.4 .86 4.7  0.4 3.7  0.1 .034
ALT (/ULN) 1.95  0.13 3.37  0.30 .001 2.54  0.18 3.16  0.36 .041
AST (/ULN) 1.49  0.08 3.00  0.06 .001 1.99  0.15 3.44  0.38 .001
ALP (/ULN) 0.58  0.02 0.72  0.34 .001 0.60  0.01 0.88  0.09 .001
AST/ALT ratio 0.65  0.02 0.74  0.03 .004 0.65  0.01 0.93  0.07 .001
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sults on blood count or liver panel. Seventy-eight patients
fulfilled the study entry criteria and comprised the valida-
tion set. Characteristics of the validation set were similar
to that of the training set, in particular, there was no
difference in the mean fibrosis score and the proportion
with significant fibrosis and cirrhosis. The 2 groups also
were comparable in platelet count and AST value. How-
ever, there were more African Americans, a higher pro-
portion with acquisition of hepatitis C through other
means besides transfusion and IDU, a higher viral load,
and a higher ALP level in the validation set (Table 1).
Models comprising platelet count and AST level for
prediction of significant fibrosis and cirrhosis were ap-
plied to the validation set. The area under ROCs (AUC)
for prediction of significant fibrosis and cirrhosis were
0.87 (95% confidence interval [CI], 0.79-0.95) and 0.93
(95% CI, 0.85-1.0), respectively. Formulas with more
variables did not improve the AUC for either significant
fibrosis or cirrhosis in the validation set (Table 3).
Novel Index in Predicting Liver Fibrosis. Because
platelet count and AST level were the most important
predictors of both significant fibrosis and cirrhosis, we
further analyzed the relationship between these 2 factors
and the stage of hepatic fibrosis. Figure 1A and B showed
that severity of liver fibrosis was correlated significantly
with a gradual increase in AST level (r  .50, P  .001) as
well as a decrease in platelet count (r  .46, P  .001).
However, there was significant overlap in AST and plate-
let among patients with different stages of fibrosis. To
amplify the difference in AST and platelet values among
patients with different fibrosis stages, we devised a novel





APRI was correlated significantly with the stage of fibro-
sis, with a higher correlation coefficient than platelet
count, or AST level alone (r  .60, P  .001) (Fig. 1C).
ROC curves of APRI for predicting significant fibrosis
and cirrhosis in the training set were plotted in Fig. 2A
with AUC of 0.80 and 0.89, respectively (Table 3). Based
on the ROC, 2 cut-off points were chosen to predict the
absence (coordinate A: APRI  0.50) or presence (coor-
dinate B: APRI  1.50) of significant fibrosis (Fig. 2A).
For patients with APRI of 0.50 or less, 47 of 55 (85%)
would not have significant fibrosis. Among the 91 pa-
tients who had significant fibrosis, only 8 (9%) would
have APRI of 0.50 or less, 7 of whom had an Ishak score
of 3 and 1 had an Ishak score of 4. For patients with APRI
greater than 1.50, 37 of 42 (88%) would have significant
fibrosis, and only 5 of 101 (5%) without significant fibro-
sis would be classified incorrectly. Together, using APRI
below the lower cut-off value (0.50) and above the higher
cut-off value (1.50), 51% of the patients could be identi-
fied correctly as either without or with significant fibrosis
(Table 4).
Similarly, 2 cut-off points were chosen to predict the
absence (coordinate C: APRI  1.00) or presence (coor-
dinate D: APRI  2.00) of cirrhosis (Fig. 2A). For pa-
tients with APRI of 1.00 or less, 123 of 126 (98%) would
not have cirrhosis. Only 3 of 28 (11%) with cirrhosis
would be classified falsely. On the other hand, for patients
with APRI greater than 2.00, 16 of 28 (57%) had cirrho-
sis, and only 12 of 164 (7%) without cirrhosis would be
identified falsely. Among the 12 patients with APRI
greater than 2.00 but who did not have cirrhosis, 1 had an
Ishak score of 2, 6 had an Ishak score of 3, and 5 had an
Ishak score of 4. Using the cut-off values of 1.00 and 2.00,
the absence or presence of cirrhosis can be identified in
81% of patients (Table 4).
Applying APRI to the validation set, AUC for predic-
tion of significant fibrosis and cirrhosis were 0.88 (95%
CI, 0.80-0.96) and 0.94 (95% CI, 0.89-1.0), respectively
(Fig. 2B). Accuracy of using APRI for prediction of sig-
nificant fibrosis and cirrhosis in the validation set is com-
parable with models with a formula comprising more
Table 3. Models With Different Combination of Variables for Predicting Significant Fibrosis and Cirrhosis
in the Training Set and the Validation Set
Variables in the Model













AST/ALT ratio NA 0.93 (0.88-0.97) NA 0.94 (0.89-0.99)
Platelets, AST, ALP 0.82 (0.76-0.88) 0.92 (0.87-0.91) 0.87 (0.80-0.95) 0.94 (0.88-1.00)
Platelets, AST 0.80 (0.74-0.86) 0.91 (0.86-0.96) 0.87 (0.79-0.95) 0.93 (0.85-1.00)
Platelets, AST/ALT ratio 0.73 (0.66-0.81) 0.90 (0.83-0.98) 0.74 (0.63-0.85) 0.90 (0.81-0.99)
APRI 0.80 (0.74-0.87) 0.89 (0.84-0.94) 0.88 (0.80-0.96) 0.94 (0.89-1.00)
NOTE. NA, not applicable because not all the variables were significant in the regression model.
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variables (Table 3). Predictive values of the APRI in the
validation set were similar to that in the training set. For
the prediction of significant fibrosis in the validation set,
the positive predictive value and negative predictive value
of an APRI of 0.50 were 64% and 90%, and the corre-
sponding values for an APRI of 1.50 were 91% and 65%,
respectively. For the prediction of cirrhosis in the valida-
tion set, the positive and negative predictive value of an
APRI of 1.00 were 35% and 100%, and the correspond-
ing values for APRI of 2.00 were 65% and 95%, respec-
tively.
Finally, we applied the models to the 270 patients from
the training and validation sets combined. For the formu-
las comprising platelet count and AST level, the AUC
were 0.82 (95% CI, 0.77-0.87) and 0.92 (95% CI, 0.87-
0.96) for prediction of significant fibrosis and cirrhosis,
respectively. For APRI, the AUC were 0.83 (95% CI,
0.78-0.88) and 0.90 (95% CI, 0.86-0.94) for prediction
of significant fibrosis and cirrhosis, respectively.
To show the use of APRI in predicting fibrosis, for a
hypothetical patient with CHC who has a platelet count
of 120  109/L and an AST level of 90 IU/L (ULN 
45), the APRI could be calculated as follows:
APRI 







This APRI value is more than 1.5 (the higher cut-off value
for significant fibrosis), so the positive predictive value for
significant fibrosis is 0.88. The APRI value is less than 2.0
Fig. 1. Box plot of (A) AST, (B) platelet count, and (C) AST platelet
ratio index in relation to the Ishak fibrosis score. The box represents the
interquartile range. The whiskers indicate the highest and lowest values,
and the asterisks represent outliers. The line across the box indicates
the median value.
Fig. 2. ROC curves of APRI in the prediction of significant fibrosis and
cirrhosis in the (A) training set and (B) validation set. An AUC of 1.0 is
characteristic of an ideal test, whereas an AUC of 0.5 or less indicates
a test of no diagnostic value.
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(the higher cut-off level for cirrhosis), so the negative pre-
dictive value for cirrhosis is 0.93. Hence, this patient is
likely to have significant fibrosis but not cirrhosis.
Discussion
In this study, we attempted to develop a single model
using routinely available laboratory test results to predict
significant fibrosis and cirrhosis in a consecutive series of
treatment-naive CHC patients. We found that platelet
count, AST level, and ALP level were the independent
predictors for significant fibrosis, whereas platelet and
white cell count, AST and ALP levels, as well as AST/ALT
ratio, were the independent predictors for cirrhosis. Our
findings echoed results from many previous studies,
which showed that platelet count, AST level, and AST/ALT
ratio were important predictors of either significant fibrosis
or cirrhosis.17-27 To amplify the opposite relationship be-
tween the stage of fibrosis and AST level and platelet count,
we devised a novel index, the APRI, which was simple to use
and had comparable accuracy with models that comprised 3
or more variables in predicting both significant fibrosis and
cirrhosis. The performance of APRI in predicting significant
fibrosis and cirrhosis was validated in a subsequent set of
patients with similar accuracy.
Many studies on prediction of significant fibrosis and
cirrhosis among CHC patients have been published in the
past few years.13-27 Our study has several unique features.
First, we recruited consecutive patients undergoing per-
cutaneous liver biopsies at our medical center who met
eligibility criteria. Many prior studies have recruited only
patients enrolled in treatment trials,18,32 which may have
introduced selection bias. Our study included treatment-
naive patients only because several studies have shown
that liver histology may improve even among nonre-
sponders to interferon-based therapy.33-35
Secondly, our study included a sufficient proportion of
patients with significant fibrosis (47%) and cirrhosis
(15%), thus allowing us to study variables that could pre-
dict both of the study endpoints within the same patient
population. Although the overall study population only
included 270 patients, and differences in race and mode
of infection were present between the training and valida-
tion sets, the accuracy of APRI was validated in a sequen-
tial cohort of CHC patients undergoing a liver biopsy at
our institution. This suggests that the model is robust and
accurate.
Most importantly, our predictive model consists of ob-
jective and readily available laboratory variables. Both
platelet count and AST level are routine tests performed
in CHC patients in clinical practice, so no additional tests
are needed. The finding of decreased platelet count and
increased AST level with progression of liver fibrosis has
been reported in many studies. With increasing fibrosis
and worsening portal hypertension, there is increased se-
questration and destruction of platelets in the enlarging
spleen.36 In addition, studies in liver transplant patients
showed that progression of liver fibrosis is associated with
decreased production of thrombopoietin by hepatocytes,
and hence reduced platelet production.37,38 Progression
of liver fibrosis may reduce the clearance of AST,39 lead-
ing to increased serum AST levels. In addition, advanced
liver disease may be associated with mitochondrial injury,
resulting in more marked release of AST, which is present
in mitochondria and cytoplasm, relative to ALT.40,41






















0.50 55 (29) 47 (47) 8 (9) 91 47 61 86
0.50 137 (71) 54 (53) 83 (91)
1.50 150 (78) 96 (95) 54 (59) 41 95 88 64






For prediction of cirrhosis
1.00 126 (66) 123 (75) 3 (11) 89 75 38 98
1.00 66 (34) 41 (25) 25 (89)
2.00 164 (85) 152 (93) 12 (43) 57 93 57 93
2.00 28 (15) 12 (7) 16 (57)
Abbreviations: PPV, positive predictive value; NPV, negative predictive value.
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To amplify the difference in AST and platelet values
among patients with different stages of fibrosis, we de-
vised a novel index, the APRI. The concept of a ratio of 2
important variables in prediction of significant fibrosis is
not new. In the study by Williams and Hoofnagle,32 the
investigators observed that as patients with chronic liver
disease progressed, AST levels increased more than ALT
levels. The investigators exploited the difference between
these 2 factors and devised the AST/ALT ratio for predic-
tion of cirrhosis. Although several investigators have con-
firmed the value of AST/ALT ratio in predicting
cirrhosis,22-25 its accuracy varies widely among studies,
with positive predictive values ranging from 0.64 to 1.00,
and negative predictive values ranging from 0.72 to 0.88,
respectively. In this study, although AST/ALT ratio was 1
of the 5 independent predictors of cirrhosis, it alone was
insufficient for accurate prediction of cirrhosis. In addi-
tion, AST/ALT ratio alone has not been shown to be
useful in predicting significant fibrosis.17-21
The APRI was accurate in predicting both significant
fibrosis and cirrhosis, with area under ROC of 0.80 and
0.89 in the training set, and 0.88 and 0.94 in the valida-
tion set, respectively. Although we could not define one
single cut-off value to predict either study endpoint, using
values below the lower cut-off level or above the higher
cut-off level, a prediction of absence or presence of cirrho-
sis could be made in 81% of patients. Similarly, a predic-
tion of absence or presence of significant fibrosis could be
made in 51% of patients. Our index compared favorably
with results from other studies. Forns et al.21 could predict
significant fibrosis in 51% of patients using 4 factors
(platelet count, -glutamyltransferase level, age, and cho-
lesterol), with an AUC of 0.94. The fibrosis index from
the MULTIVIRC group could predict significant fibrosis
in 46% of patients by using a combination of 6 markers
(2 macroglobulin, haptoglobin,  globulin, apolipop-
totein A1,  glutamyl-transpeptidase, and total bilirubin),
with an AUC of 0.84.15 Although the value of the index of
Forns et al.21 in predicting the absence of significant fi-
brosis was better than the APRI, it involved a complicated
formula. The major advantage of the APRI is its simplic-
ity. APRI can be determined in the clinic or bedside with-
out the help of a calculator. Moreover, the APRI allows
clinicians to use one formula to predict significant fibrosis
as well as cirrhosis.
Although our study was retrospective in design, we
took all the necessary measures to maximize the accuracy
of our data collection. To ensure consistency in data ex-
traction, a predetermined set of criteria for all subjective
variables was established before the medical records were
reviewed, and all data extraction was performed by one
investigator (C.T.W.). The key variables in our study
were objective laboratory results, most of which were
available in the hospital computer system. All histologic
slides were retrieved and re-read by one liver pathologist
(J.K.G.) to avoid interobserver discrepancy. In addition,
all the slides were re-read over a 12-week period to mini-
mize intraobserver variability.
We acknowledge that there are limitations to our
study. Our study included patients from a university
hepatology clinic, half of whom had significant fibrosis on
histology and none had prior antiviral treatment.
Whether our results can be generalized to community-
based practice in which patients may have milder disease,
or to patients who failed prior antiviral therapy remain to
be determined. Despite the simplicity and accuracy of the
APRI, there was overlap among patients with different
stages of fibrosis. Thus, the use of APRI in the prediction
of fibrosis in individual patients with CHC must be con-
firmed in prospective studies. Finally, our study is based
on the premise that liver biopsy is the gold standard for
assessing hepatic fibrosis, but sampling error as well as
intra- and interobserver variability can complicate the
correlations between histology and noninvasive markers
of hepatic fibrosis.
In conclusion, we showed that a simple index, the
APRI, consisting of 2 readily available laboratory results
(AST level and platelet count), can predict significant
fibrosis and cirrhosis in treatment-naive CHC patients
with a very high degree of accuracy. Our results were
validated in a subsequent cohort of CHC patients at our
institute. The APRI can be determined in the clinic or at
the bedside. Using one simple formula, significant fibrosis
and cirrhosis can be predicted accurately in 51% and 81%
of treatment-naive CHC patients, respectively, potentially
avoiding the need for liver biopsies in these patients. Further
prospective studies are needed to validate the APRI in a larger
number of CHC patients in other institutes, in particular,
community-based practices where the prevalence of signifi-
cant fibrosis and cirrhosis may be lower, and in patients who
had received antiviral therapy previously.
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